Literature DB >> 27223084

Association of miR-608 rs4919510 polymorphism and cancer risk: a meta-analysis based on 13,664 subjects.

Huiquan Liu1, Yaqun Zhou2, Qingquan Liu3, Guangqin Xiao4, Bangyan Wang1, Weijuan Li1, Dawei Ye1, Shiying Yu1.   

Abstract

Single nucleotide polymorphisms (SNPs) in MicroRNAs (miRNAs) are involved in the mechanism of carcinogenesis. Several studies have evaluated the association of rs4919510 SNP in miR-608 with cancer susceptibility in different types of cancer, with inconclusive outcomes. To obtain a more precise estimation, we carried out this meta-analysis through systematic retrieval from the PubMed and Embase database. A total of 10 case-control studies were analyzed with 6,000 cases and 7,664 controls. The results showed that 4919510 SNP in miR-608 was significantly associated with decreased cancer risk only in recessive model (CC vs. GG+GC: OR=0.89, 95% CI: 0.82-0.97, P=0.009). By further stratified analysis, we found that rs4919510 SNP had some relationship with decreased cancer risk in both homozygote model (CC vs. GG: OR=0.59, 95% CI: 0.36-0.96, P=0.034) and dominant model (CG+ CC vs. GG: OR=0.60, 95% CI: 0.37-0.98, P=0.042) in Caucasians but no relationship in any genetic model in Asians. These results indicated that miR-608 rs4919510 polymorphism may contribute to the decreased cancer susceptibility and could be a promising target to forecast cancer risk for clinical practice. However, to further confirm these results, well-designed large scale case-control studies are needed in the future.

Entities:  

Keywords:  cancer risk; meta-analysis; miR-608; polymorphism; rs4919510

Mesh:

Substances:

Year:  2017        PMID: 27223084      PMCID: PMC5514889          DOI: 10.18632/oncotarget.9509

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

MicroRNAs (miRNAs) are small (usually 21–23 nucleotides in length), evolutionarily conserved, noncoding RNA molecules which participate in post-transcriptional gene regulation by binding to the complementary sequences in 3’ untranslated region (3’ UTR) of target messenger RNAs (mRNAs) [1, 2]. These miRNAs function as negative regulators through degradation of mRNAs and translational repression [3]. Accumulated evidence has suggested that the aberrations of these miRNAs are involved in cell proliferation, differentiation, migration and apoptosis in the process of carcinogenesis [4, 5]. Studies have shown that approximately 50% miRNA genes are located in cancer-related chromosomal regions [6]. The loss or gain of specific function of several miRNAs are thought to be significant events in diverse types of cancer [7]. These evidences indicated that microRNAs could be a kind of biomarkers to evaluate cancer risk. Single nucleotide polymorphisms (SNPs), the most common genetic variation, have been demonstrated to influence the expression or target site selection of miRNAs and thus are involved in a series of biological processes by interfering interaction between miRNAs and target mRNAs [8, 9]. SNPs present in the miRNA genes have been illustrated to be a potentially important mechanism in the development and progression of cancer [10, 11]. Recently, rs4919510 SNP in miR-608 has been reported to be a predictor of clinical outcomes for patients with renal cell carcinoma [12], colorectal adenocarcinoma [13, 14], esophageal squamous cell carcinoma [15] and nasopharyngeal carcinoma [16]. However, the relationship between cancer risk and rs4919510polymorphism in miR-608 is now inconclusive and controversial. Qiu and colleagues had found that rs4919510 (C > G) polymorphism showed a consistent association with nasopharyngeal carcinoma susceptibility in south area of China [17]. Other study reported that there existed no significant association between miRNA-608 rs4919510 and the risk of colorectal cancer [18]. By systematically summarizing the existing data, we performed a meta-analysis to further determine whether there is an association of rs4919510 polymorphism in miR-608 with cancer susceptibility.

RESULTS

Characteristics of the studies

A total of 51 literatures based on our searching strategy were selected out from PubMed and EMBASE database. After screening the title and abstract, 25 studies uncorrelated with cancer risk and SNPs were excluded and 26 literatures were then evaluated in detail. Finally ten case-control studies [17-26] meeting our inclusion criteria were included into our meta-analysis with 6,000 cases and 7,664 controls (Figure 1) (Table 1). One article composed by Ryan and colleagues contains two case-control studies with detailed genotype information of Caucasian and African Americans. To perform subgroup analysis more conveniently, we regarded this one as two independent studies according to ethnicity. In all included studies, genotype distributions of rs4919510(C > G) in the controls were in agreement with HWE. A variety of genotyping methods were applied including Taqman, RT-PCR, MassArray, SNaPshot, and SNPstream. Genomic DNA was isolated from blood samples in all included studies except one (using both blood and tissue) [18].
Figure 1

Study flow chart for the process of selecting the eligible publications

Table 1

Characteristics of studies in the meta-analysis

AuthorYearcountryEthnicityCancer typeGenotypingSource of controlsCases(n)Controls(n)P value for HWE h
TotalGGGCCCTotalGGGCCC
Dong2015ChinaAsianThyroid tumorMassArrayHB f369136186477512793701020.494
Zhang2015ChinaAsianESCC bSNaPshotPB g7382173841378822914401510.784
Yin2015ChinaAsianLung cancerTaqmanHB258651405331096152620.992
Wei2015ChinaAsianThyroid tumorMassArrayPB82426642813010313265032020.950
Qiu2015ChinaAsianSCCHN cTaqManPB90625546019110722545322860.977
Wang2014ChinaAsianHCC dMassArrayHB9933045001899923184971770.775
Huang2012ChinaAsianBreast cancerSNPstreamPB111838154519214174566842770.776
Kupcinskas2014LithuaniaCaucasianGastric cancerRT-PCRHB363258825035013862510.275
Kupcinskas2014LithuaniaCaucasianCRC eRT-PCRHB19274713842612963180.364
Ryan2012USAMixed races aCRCTaqmanPB/HB2391996124433361662310.729

a Caucasian and African Americans; b ESCC esophageal squamous cell carcinoma; c SCCHN squamous cell carcinoma of the head and neck; d HCC hepatocellular carcinoma; e CRC colorectal cancer; f HB hospital-based; g PB population-based; h HWE Hardy-Weinberg equilibrium.

a Caucasian and African Americans; b ESCC esophageal squamous cell carcinoma; c SCCHN squamous cell carcinoma of the head and neck; d HCC hepatocellular carcinoma; e CRC colorectal cancer; f HB hospital-based; g PB population-based; h HWE Hardy-Weinberg equilibrium.

Meta-analysis result

The main results of this meta-analysis were shown in Table 2. For overall studies, there existed a significant association of miR-608 rs4919510 polymorphism with decreased cancer risk only in recessive model (CC vs. GG+GC: OR=0.89, 95% CI: 0.82-0.97, P=0.009) (Figure 2). In other genotype model, the relationship still remain controversial.
Table 2

The result of meta-analysis for various genotype models

Test of AssociationP Value for heterogeneityI2 (%)
OR (95%CI)bZP Value
TotalaCC vs. GG0.90 (0.77,1.06)1.230.219c0.03151.1%
CG vs. GG1.01 (0.93,1.10)0.310.754d0.3618.8%
CG+CC vs.GG0.98 (0.88,1.10)0.280.776c0.09339.7%
GG+GC vs.CC0.89 (0.82,0.97)2.610.009d0.26819.0%
AsianCC vs. GG0.93 (0.77,1.11)0.810.418c0.01661.6%
CG vs. GG1.02 (0.94,1.11)0.510.610d0.3539.9%
CG+CC vs.GG1.00 (0.89,1.12)0.010.988c0.07947.0%
GG+GC vs.CC0.90 (0.79,1.03)1.510.130c0.09045.3%
CaucasianCC vs. GG0.59 (0.36,0.96)2.120.034d0.8320.0%
CG vs. GG0.65 (0.39,1.09)1.630.103d0.7270.0%
CG+CC vs.GG0.60 (0.37,0.98)2.030.042d0.8020.0%
GG+GC vs.CC0.84 (0.68,1.04)1.560.118d0.8760.0%

aContrasts including homozygote model (CC vs. GG), heterozygote model (CG vs. GG), dominant model (CG+ CC vs. GG) and recessive model (CC vs. GG+GC) respectively.

bR odds ratio, CI confidence interval.

cP-value for significance under random-effects model.

dP-value for significance under fixed-effects model.

Figure 2

Overall meta-analysis of the relationship between miR-608 rs4919510 polymorphism and cancer risk in recessive model (CC vs. GG+GC)

aContrasts including homozygote model (CC vs. GG), heterozygote model (CG vs. GG), dominant model (CG+ CC vs. GG) and recessive model (CC vs. GG+GC) respectively. bR odds ratio, CI confidence interval. cP-value for significance under random-effects model. dP-value for significance under fixed-effects model. For subgroup analysis of races, we found that in Caucasians miR-608 rs4919510 polymorphism had some relationship with decreased cancer risk in both homozygote model (CC vs. GG: OR=0.59, 95% CI: 0.36-0.96, P=0.034) and dominant model (CG+ CC vs. GG: OR=0.60, 95% CI: 0.37-0.98, P=0.042) (Figure 3). In Asians, Our results did not show any association of miR-608 rs4919510 polymorphism with cancer risk in any genotype model (Figure 4).
Figure 3

Subgroup analysis of the relationship between miR-608 rs4919510 polymorphism and cancer risk in Caucasians

A. homozygote model (CC vs. GG); B. heterozygote model (CG vs. GG); C. dominant model (CG+ CC vs. GG); D. recessive model (CC vs. GG+GC).

Figure 4

Subgroup analysis of the relationship between miR-608 rs4919510 polymorphism and cancer risk in Asians

A. homozygote model (CC vs. GG); B. heterozygote model (CG vs. GG); C. dominant model (CG+ CC vs. GG); D. recessive model (CC vs. GG+GC).

Subgroup analysis of the relationship between miR-608 rs4919510 polymorphism and cancer risk in Caucasians

A. homozygote model (CC vs. GG); B. heterozygote model (CG vs. GG); C. dominant model (CG+ CC vs. GG); D. recessive model (CC vs. GG+GC).

Subgroup analysis of the relationship between miR-608 rs4919510 polymorphism and cancer risk in Asians

A. homozygote model (CC vs. GG); B. heterozygote model (CG vs. GG); C. dominant model (CG+ CC vs. GG); D. recessive model (CC vs. GG+GC).

Publication bias and sensitivity analysis

We utilized Funnel Plot, Begg's funnel plot and Egger's test to evaluate publication bias. The almost symmetrical shape of the funnel plots for four genetic models did not reveal any significant publication bias (Figure 5). There was also no evidence of publication bias in Begg's funnel for all genetic models (P > 0.05)(Figure 6). We also did not find out publication bias in Egger's test in homozygote model (CC vs. GG, P= 0.977), heterozygote model (CG vs. GG, P=0.744), dominant model (CG+ CC vs. GG, P=0.772) and recessive model (CC vs. GG+GC, P=0.440). Sensitivity analysis through evaluating the influence of each study on overall ORs showed that the omission of any study made no significant difference (Figure 7).
Figure 5

Funnel plot for publication bias test

A. homozygote model (CC vs. GG); B. heterozygote model (CG vs. GG); C. dominant model (CG+ CC vs. GG); D. recessive model (CC vs. GG+GC).

Figure 6

Begg's funnel plot for publication bias test

A. homozygote model (CC vs. GG); B. heterozygote model (CG vs. GG); C. dominant model (CG+ CC vs. GG); D. recessive model (CC vs. GG+GC).

Figure 7

The influence of individual studies on the overall OR in recessive model (CC vs. GG+GC)

Funnel plot for publication bias test

A. homozygote model (CC vs. GG); B. heterozygote model (CG vs. GG); C. dominant model (CG+ CC vs. GG); D. recessive model (CC vs. GG+GC).

Begg's funnel plot for publication bias test

A. homozygote model (CC vs. GG); B. heterozygote model (CG vs. GG); C. dominant model (CG+ CC vs. GG); D. recessive model (CC vs. GG+GC).

DISCUSSION

Genetic mutations are responsible for cancer occurrence [27]. SNPs as the most common genetic sequence variation, could affect the function of a series of microRNAs by altering the formation of the primary transcript, pre-miRNA maturation, or miRNA-mRNA interactions [10, 28]. Recently, rs4919510 polymorphism in miR-608 has been reported to predict clinical outcomes for cancer patients in different cancer types [13, 14, 16]. In addition, Zhang and colleagues found that miR-608 expressions were reduced in chordoma cell lines and restoration of miR-608 inhibited chordoma cell proliferation and invasion [29]. All these studies provoked us to think about the association of miR-608 polymorphism and cancer risk. In this meta-analysis, we demonstrated that individuals carrying CC genotype in rs4919510 have a decreased cancer risk. Moreover, Yang and colleagues reported that miR-608 suppressed the carcinogenesis of colon cancer cells in vitro and in vivo by eliminating NAA10 mRNA which participate as a key molecule in the process of carcinogenesis [30]. Taken together, these results strongly indicated that genetic variation of rs4919510 in miR-608 played an important role in cancer development. By subgroup analysis, we found that in Caucasians miR-608 rs4919510 polymorphism had some relationship with decreased cancer risk in homozygote model and dominant model while in Asians there exist no relationship in any genotype model. These differences may be a result of various genetic backgrounds in different races and various mechanisms of carcinogenesis in different areas. Nevertheless, some limitations in this meta-analysis should be paid attention to. First, included studies are still so limited that we cannot perform subgroup analysis for different cancer types although it is well known that one microRNA may play different functions in different types of cancer. Second, there exists a certain degree of heterogeneity between studies. After subgroup analysis stratified by races, it could be found that heterogeneity of Caucasians reduced significantly. Thus, it could be presumed that the heterogeneity partly resulted from differences in races. Simultaneously, the selection of subjects may become another source of heterogeneity. Third, only three studies were included in subgroup analysis for Caucasians and the results could be inaccurate and dubious. Fourth, only published articles were included, the unpublished and ongoing studies could convert our result. Last, we did not take sex, age, sex, family history and environmental factors into consideration and further detailed meta-analysis remain needed. In conclusion, the results of meta-analysis indicated that rs4919510(C > G) polymorphism in miR-608 was significantly associated with decreased cancer risk and could become a promising target to forecast cancer risk for clinical practice. However, these results should be treated with caution due to the limitations above. For further verifying the results, well-designed large scale case–control studies are needed in the future.

MATERIALS AND METHODS

Publication search and data extraction

To identify all published studies concerning the relationship between miRNA polymorphisms and cancer risk, PubMed and Embase database (updated to Jan 1, 2016) were searched without language, publication, or date restrictions using the following search terms: (“microRNA 608” OR “microRNA-608” OR “miR-608” OR “rs4919510”) AND (“polymorphism” OR “SNP” OR “variation” OR “locus” OR “mutation”) AND (“cancer” OR “tumor” OR “malignance” OR “carcinoma” OR “neoplasm”). The included papers should meet criteria listed below: (1) Assessment of the relationship between miR-608 rs4919510 polymorphism and cancer risk; (2) a case-control design; (3) histologically confirmed for malignant tumors; (4) sufficient published data for further calculating odds ratios (ORs) and their 95% confidence intervals (95%CIs); (5) Meeting Hardy-Weinberg equilibrium (HWE) in the control group (P>0.05). Two reviewers (HQ Liu and BY Wang) in our group screened out the data independently and had reached a consensus on each term. All extracted data consisted of author (year), country, ethnicity, cancer type, genotyping method, source of controls, characteristics of cases and controls and P value for Hardy–Weinberg equilibrium (HWE) was exhibited in Table 1.

Statistical analysis

We calculated P value of HWE in control group by X2 test and considered P value>0.05 as fulfilling Hardy-Weinberg equilibrium [31]. The association between the miR-608 rs4919510 (C > G) SNP and the risk of cancer was measured by odds ratios (ORs) with 95% confidence intervals (CIs) based on different genetic models such as homozygote model (CC vs. GG), heterozygote model (CG vs. GG), dominant model (CG+ CC vs. GG) and recessive model (CC vs. GG+GC) respectively. Hierarchical analysis was conducted by Ethnicity (Asian and Caucasian). The statistical significance of the pooled OR was evaluated by Z test, and P value of <0.05 was regarded as significant. Heterogeneity assumption was tested among studies using a Chi-square-based Q-test. We considered P value of > 0.10 for Q-test as a lack of heterogeneity which indicate fixed-effects model should be used to perform the meta-analysis [32]. If significant heterogeneity was existing (P<0.10 for Q-test), the random effects model should be chosen as a more appropriate one [33]. To evaluate whether there existed publication bias, Funnel plots, Begg's test and Egger's test were applied [34]. The influence of each study on overall OR was also evaluated using metaninf order. Statistical analysis was all conducted using Stata12.0 Software.
  34 in total

1.  Association between the pre-mir-218 polymorphism and cancer risk in the Chinese population: a meta-analysis.

Authors:  Yue Gao; Yan Liu; Ge-Li Liu; Long-Ke Ran; Fan Zeng; Jia-Yan Wu; Fang-Zhou Song
Journal:  Asian Pac J Cancer Prev       Date:  2014

Review 2.  MicroRNAs: small RNAs with big effects.

Authors:  Dany Anglicheau; Thangamani Muthukumar; Manikkam Suthanthiran
Journal:  Transplantation       Date:  2010-07-27       Impact factor: 4.939

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

4.  A sequence polymorphism in miR-608 predicts recurrence after radiotherapy for nasopharyngeal carcinoma.

Authors:  Jian Zheng; Jieqiong Deng; Mang Xiao; Lei Yang; Liyuan Zhang; Yonghe You; Min Hu; Na Li; Hongchun Wu; Wei Li; Jiachun Lu; Yifeng Zhou
Journal:  Cancer Res       Date:  2013-06-24       Impact factor: 12.701

5.  Association study of single nucleotide polymorphisms in mature microRNAs and the risk of thyroid tumor in a Chinese population.

Authors:  Wen-Jun Wei; Yu-Long Wang; Duan-Shu Li; Yu Wang; Xiao-feng Wang; Yong-Xue Zhu; Xue-Dong Pan; Zhuo-Ying Wang; Yi Wu; Li Jin; Jiu-Cun Wang; Qing-Hai Ji
Journal:  Endocrine       Date:  2014-11-09       Impact factor: 3.633

Review 6.  Alterations of microRNAs contribute to colon carcinogenesis.

Authors:  Aaron J Schetter; Curtis C Harris
Journal:  Semin Oncol       Date:  2011-12       Impact factor: 4.929

7.  Association study of miR‑149 rs2292832 and miR‑608 rs4919510 and the risk of hepatocellular carcinoma in a large‑scale population.

Authors:  Rui Wang; Jun Zhang; Yanyun Ma; Linqi Chen; Shicheng Guo; Xiaojiao Zhang; Yunfang Ma; Lijun Wu; Xiaoyu Pei; Siran Liu; Jiucun Wang; Heping Hu; Jie Liu
Journal:  Mol Med Rep       Date:  2014-09-04       Impact factor: 2.952

Review 8.  Oncogenic MicroRNAs: Key Players in Malignant Transformation.

Authors:  Tania Frixa; Sara Donzelli; Giovanni Blandino
Journal:  Cancers (Basel)       Date:  2015-12-18       Impact factor: 6.639

9.  Polymorphism rs4919510:C>G in mature sequence of human microRNA-608 contributes to the risk of HER2-positive breast cancer but not other subtypes.

Authors:  A-Ji Huang; Ke-Da Yu; Jing Li; Lei Fan; Zhi-Ming Shao
Journal:  PLoS One       Date:  2012-05-07       Impact factor: 3.240

10.  microRNA-342-5p and miR-608 inhibit colon cancer tumorigenesis by targeting NAA10.

Authors:  Hongju Yang; Qian Li; Jie Niu; Bai Li; Dejun Jiang; Zhihua Wan; Qingmei Yang; Fei Jiang; Ping Wei; Song Bai
Journal:  Oncotarget       Date:  2016-01-19
View more
  9 in total

1.  Influence of variants of the drosha, mir499a, and mir938 genes on susceptibility to acute lymphoblastic leukemia in an admixed population from the brazilian amazon.

Authors:  Tatiane Piedade de Souza; Darlen Cardoso de Carvalho; Alayde Viera Wanderley; Sweny Marinho Fernandes; Juliana Carla Gomes Rodrigues; Amanda Cohen-Paes; Marianne Rodrigues Fernandes; Fernando Augusto Rodrigues Mello Junior; Lucas Favacho Pastana; Lui Wallacy Morikawa Souza Vinagre; Artur Luiz da Costa Silva; Paulo Pimentel de Assumpção; Sidney Santos; André Salim Khayat; Ney Pereira Carneiro Dos Santos
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

2.  A meta-analysis: Is there any association between MiR-608 rs4919510 polymorphism and breast cancer risks?

Authors:  Jing Wang; Xiangyi Kong; Zeyu Xing; Xiangyu Wang; Jie Zhai; Yi Fang; Jidong Gao
Journal:  PLoS One       Date:  2017-08-22       Impact factor: 3.240

3.  A PRISMA-compliant meta-analysis of MDM4 genetic variants and cancer susceptibility.

Authors:  Yajing Zhai; Zhijun Dai; Hairong He; Fan Gao; Lihong Yang; Yalin Dong; Jun Lu
Journal:  Oncotarget       Date:  2016-11-08

4.  MicroRNA‑608 sensitizes non‑small cell lung cancer cells to cisplatin by targeting TEAD2.

Authors:  Yanli Wang; Fengcai Li; Dandan Ma; Yuhua Gao; Runpu Li; Yingjie Gao
Journal:  Mol Med Rep       Date:  2019-08-26       Impact factor: 2.952

5.  Genetic variation of the gene coding for microRNA-204 (miR-204) is a risk factor in acute myeloid leukaemia.

Authors:  Aleksandra Butrym; Piotr Łacina; Kazimierz Kuliczkowski; Katarzyna Bogunia-Kubik; Grzegorz Mazur
Journal:  BMC Cancer       Date:  2018-01-30       Impact factor: 4.430

Review 6.  microRNAs Make the Call in Cancer Personalized Medicine.

Authors:  Simone Detassis; Margherita Grasso; Valerio Del Vescovo; Michela A Denti
Journal:  Front Cell Dev Biol       Date:  2017-09-22

7.  No Association Between MicroRNA-608 rs4919510 G>C Polymorphism and Digestive System Cancers Susceptibility: A Meta-Analysis Based on 10,836 Individuals.

Authors:  Xue-Feng Li; Ju-Kun Song; Jun-Wei Cai; Yu-Qin Zeng; Min Li; Jie Zhu; Yu-Ming Niu
Journal:  Front Physiol       Date:  2018-06-07       Impact factor: 4.566

8.  The role of microRNA-608 polymorphism on the susceptibility and survival of cancer: a meta-analysis.

Authors:  Zhi-Ming Dai; Jian-Rui Lv; Kang Liu; Xiao-Ming Lei; Wei Li; Gang Wu; Xing-Han Liu; Yu-Xiao Zhu; Qian Hao; Zhi-Jun Dai
Journal:  Aging (Albany NY)       Date:  2018-06-16       Impact factor: 5.682

9.  The association between polymorphisms in microRNA genes and cervical cancer in a Chinese Han population.

Authors:  Li Chuanyin; Wang Xiaona; Yan Zhiling; Zhang Yu; Liu Shuyuan; Yang Jie; Hong Chao; Shi Li; Yang Hongying; Yao Yufeng
Journal:  Oncotarget       Date:  2017-09-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.